Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS)

Q: What does CUSIP 171126204 represent in this 13F holders report?

CUSIP 171126204 is the security identifier for PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share in Q4 2025?

15 institutional investors reported PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 171126204

Q4 2025 13F Holders as of 31 Dec 2025

Security type / class: Equity / Common Stock, par value $0.0001 per share
Total 13F shares: 899,359
Total 13F value: $27,880,129
Share change: +436,597
SEC-reported price per share: $31.00
Number of holders: 15
Value change: +$13,536,994
Number of buys: 14
Number of sells: 3
Shares outstanding: 3,332,442

Security key

171126204

Report period

Q4 2025

Institutions

Top holders

PTHS full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2026 Previous quarter: Q3 2025 Pelthos Therapeutics Inc. SEC filings Pelthos Therapeutics Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 171126204

Newer quarter: Q1 2026 Previous quarter: Q3 2025

Recent filing periods:

Q2 2026 Q1 2026 Q4 2025 Q3 2025

Ownership snapshot

Top reported holders of PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

LIGAND PHARMACEUTICALS INC

Disclosed value leader

LIGAND PHARMACEUTICALS INC

Comparable rows

15/15

Latest evidence

23 Dec 2025

13D/G 3/4/5 13F Lead comparable stake: 50% 13D/G row: LIGAND PHARMACEUTICALS INC Showing 1-6 of 15 holder rows.

Quick read

LIGAND PHARMACEUTICALS INC leads the comparable SEC ownership view at 50%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens LIGAND PHARMACEUTICALS INC's linked filing trail.

Comparable ownership Top 5

LIGAND PHARMACEUTICALS INC 50%

Alexandra Wood (Canada) Inc. 9.5%

Murchinson Ltd. 9.1%

Ezra M. Friedberg 8.3%

Ikarian Capital, LLC 7.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
LIGAND PHARMACEUTICALS INC	13D/G 3/4/5 Ligand Pharmaceuticals Incorporated · Director, 10%+ Owner 13D/G 3/4/5	50%	$145,296,959 5,189,177 shares	+$7,316,652	06 Nov 2025
Alexandra Wood (Canada) Inc.	13D/G 13D/G	9.5%	$734,959 574,187 shares	$0	13 Dec 2024
Murchinson Ltd.	13D/G 13F Company 13D/G 13F	9.1%	$7,840,000 280,000 shares	$0	30 Sep 2025
Ezra M. Friedberg	13D/G Ezra Friedberg 13D/G	8.3%	— 250,121 shares	$0	01 Jul 2025
Ikarian Capital, LLC	13F 13D/G Company 13F 13D/G	7.3% from 13D/G	$1,748,628 62,451 shares	—	30 Sep 2025
Andrew J. Einhorn	3/4/5 Director 3/4/5	0.36%	$342,000 12,000 shares	—	23 Dec 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

899,359

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 value	Q4 2025 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend